Wockhardt Ltd.
Fundamentals
- Market cap
- ₹31,933 cr
- P/E
- 149.92×
- ROE
- 0.00%
- Debt / equity
- 0.43
- 52-week range
- 1086.70 — 2422.30
Company snapshot
Wockhardt Ltd.
Pharmaceuticals
₹31,671 cr
P/E 148.69×
Latest quarter · Mar 2026
Sales₹965 cr
Net profit₹164 cr
Op. margin+23.3%
EPS₹10.25
Strength & growth
Debt / equity0.43×
Current ratio1.21×
Sales CAGR−2.7%
EPS CAGR−4.8%
The timeline — 3 notes on Wockhardt Ltd.
May 2026
- 30 May 26 · 8:19 PM IST Alert Alert · Large cap
Wockhardt's ZAYNICH wins FDA approval, first novel drug from an Indian pharma
The antibiotic beat meropenem in a 530-patient trial, validating a 15-year R&D pivot and opening a US market with 600,000+ annual hospitalisations.
- 21 May 26 · 2:42 PM IST Brief Brief · Credit · Large cap
Wockhardt's credit quality just improved — but the market already knew
ICRA upgraded the pharma company to A- (Stable) from BBB (Positive), reflecting better finances and market position. The move was widely anticipated.